Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ISRCTN12338815) titled 'A first-in-human study to test the safety and tolerability of an experimental medicine (CVTX-55832), given at different dose levels, in healthy volunteers' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Parallel
Purpose: Treatment
Primary Sponsor: Covant Therapeutics Operating, Inc
Condition:
Healthy volunteers
Other
Intervention:
Method of randomization: Participants are allocated to CVTX-55832 or matching placebo (6:2 within each cohort) using a computer-generated permuted block randomisation sched...